VPC 44116
(R)-(3-amino-4-((3-octylphenyl)amino)-4-oxobutyl)phosphonic acid
In addition to receptor-selective agonists such as SEW2871, competitive S1P receptor antagonists have provided insight into the physiological effects of S1P signaling, particularly involving S1P1.(R)-3-amino-(3-octylphenylamino)-4-oxobutylphosphonic acid (VPC44116) (S1P1/3 antagonist) and an analog, (R)-3-amino-(3-hexylphenylamino)-4-oxobutylphosphonic acid (W146) (S1P1 antagonist), both were found to increase capillary permeability as measured by Evans blue dye leakage in mouse lung tissue.Kennedy, P.C., et al. (2011).Also refer Sanna et al., 2006 and Foss et al., 2007.
This product is covered by Patent Number US 7,888,527 B2. Avanti manufactures this under license from University of Virginia